MP Group: Outlook on the CROs for the new-age Biopharma

It is our pleasure to share with you our outlook on the ‘CROs for the new-age Biopharma’. The drug development landscape is rapidly shifting towards complex targets and new drug modalities, with growth in cell & gene therapy and ADC pipeline now outpacing traditional small molecule drug candidates. As a result, the Biopharma cos are seeking CROs that can become an extension of their scientific think-tank, providing intellectual inputs and cutting edge research insights. It will be critical for CROs…

Continue Reading

MP Group: Outlook on the mRNA Bio-CDMOs – A key catalyst for the evolution of mRNA therapeutics

It is our pleasure to share with you our outlook on the ‘mRNA Bio-CDMOs – A key catalyst for the evolution of mRNA therapeutics.’ mRNA therapeutics played a pivotal role in the pandemic management thereby generating unparalleled interests (and investments) across the biopharma as well as investor groups. mRNA Covid-19 vaccines have paved the pathway for regulatory approvals. As a result, the clinical pipeline of mRNA therapeutics has expanded several fold across wide range of indications beyond infectious disease such…

Continue Reading

MP Group – A Global Outlook of HEOR (Health Economics and Outcomes Research) Services

We are glad to share our global outlook on Health Economics and Outcomes Research (HEOR) services. The field of Health Economics and Outcomes Research (HEOR) has undergone a significant transformation, shifting from a supportive role to a prominent position in the launch of drug products in the past decade. With the rising research and development costs, innovative therapeutic approaches and government initiative to curtail healthcare expenditures, we anticipate a persistent rise in the demand for HEOR services to demonstrate the…

Continue Reading

Pharmaphorum: Global upswing in medical writing, with a bout of M&A

The pharma industry has witnessed tremendous growth in the last decade with COVID-19 further fuelling the development of potential treatments, diagnostics, and vaccines at an unprecedented pace. There are now over 5000 companies involved in pharma R&D globally, approximately double that in 2012. The global pharma R&D spending increased from ~$130 billion in 2012 to ~$240 billion in 2022, leading to a doubling of the pipeline drug count. This swift pharma R&D growth has in turn accelerated the growth of…

Continue Reading

Digital Health Innovation: key stakeholders empowering the ecosystem

Technology is becoming an integral part of our lives, making its way into every industry from pharma to aviation. Thus, it is no surprise that it has also gained a strong foothold in driving decisions for better health. The application of digital health is widespread with well-being and fitness apps found on all our phones, from calorie tracker and meditation apps to guided exercises and medication adherence reminders. The umbrella of digital health has 2 specialized sections: Digital Medicine and…

Continue Reading

MP Group: Outlook on ‘Promise of Digital Health-2022’

We are glad to present our outlook on ‘Promise of Digital Health-2022’. The presentation outlines the potential of digital health in transforming healthcare delivery and associated opportunities for the biopharma industry. Digital health solutions are increasingly demonstrating its value towards a number of facets of healthcare delivery - from patient-centric apps for personalised content, guidance and medication adherence, sensors/wearables for real time monitoring, and remote access to health systems like teleconsultations, all of which aimed towards improved healthcare outcomes. Beyond improved…

Continue Reading

MP Group: Outlook on ‘Artificial Intelligence in Target and Biomarker Discovery-2022′

We are glad to present our outlook on ‘Artificial Intelligence in Target and Biomarker Discovery-2022’. The attached presentation outlines how AI can better elucidate disease biology and assist with building a robust hypothesis for target and biomarker identification. Most clinical trials fail because of poor safety and efficacy resultant from a lack of holistic disease understanding. The traditional approaches are usually unidimensional and fail to account for the complex nature of biology. While we are observing an explosion of healthcare data,…

Continue Reading

Biopharma Trend: 7 Tips for Growing a Successful ‘AI in Pharma’ Business: Key Growth Strategy Lessons

The ‘AI in Pharma’ start-up space has been rapidly exploding, with new companies being formed every month. The explosion has been fueled by slow yet steady adoption of such tools by the biopharma companies. However, it’s only a handful number of start-ups that are garnering all the attention while others are struggling to even get a single ‘paid’ project. Several start-ups are likely to die within 2 years, even when they had built great products/ services. A good idea or…

Continue Reading

Outlook on AI and medical writing

We are glad to present our outlook on ‘AI and medical writing’ that gives an overall perspective on the technological advancements in the medical writing industry. Medical writing is expected to be a $5B+ market with a ~10% CAGR in the next 5 years. However, the industry faces the challenge of high attrition rates and lack of resources. Inefficiencies are further fueled by limited use of automation to reuse content between different regulatory documents and publications as well as limited…

Continue Reading

MP Group: Outlook on Microphysiological Systems (MPS) – The future of pre-clinical R&D

Outlook on ‘Microphysiological Systems (MPS) – The future of pre-clinical R&D’ that outlines the challenges with traditional drug testing, alternatives to the traditional methods, and the current and future perspective on MPS technologies. With a ~90% failure rate of drugs in clinical trials, the biopharma R&D continues to operate with substandard efficiency. The traditional drug testing methods (in-vitro and in-vivo) often fail to translate into clinical observations. Therefore, there is a high unmet need to develop in-vitro systems offering improved…

Continue Reading
Close Menu